Although our study has concentrated on boosting TFEB levels during infection, the efficacy of DCAF7 inhibitors to modulate TFEB activity under basal conditions suggests potential application of this approach for other, noninfectious conditions associated with impaired autolysosomal activity. Here, TFEB is linked to infection.